U.K.-based pharmaceutical company GlaxoSmithKline, popularly known as GSK, signed an R&D agreement with Syngene International, a global contract research services company based in Bangalore, India. The multi-year agreement will focus on accelerating the discovery of new drug candidates with the potential to address some of the world’s most pressing healthcare needs.
Syngene will set up a customized discovery research laboratory to support projects across several therapeutic areas, and a team of its scientists will work closely with GSK’s global R&D teams on discovery research projects. Syngene employs more than 3,000 scientists in India.
Jonathan Hunt, chief executive officer, Syngene International said, “GSK is a global industry leader and we believe Syngene’s scientific capabilities and expertise will complement GSK’s efforts to discover and develop new medicines to benefit patients worldwide.”
